Case 2 was a middle-aged female patient from the EGFR+/METamp + group, who was a nonsmoker and was diagnosed with advanced lung adenocarcinoma with brain metastases….Considering that the patient was still harboring the EGFR exon 19 deletion and MET amplification, a combination therapy of osimertinib and savolitinb was selected for the next follow-up regimen. A chest CT scan revealed considerable reduction of the primary tumor and malignant pleural effusion. The patient had PR for nearly 4 years until the follow-up date, and her ECOG PS was 1.